Revealing the ubiquitin and ubiquitin like modification landscape in health and...
Revealing the ubiquitin and ubiquitin like modification landscape in health and disease
Post-translational modifications (PTMs) of proteins are a major tool that the cell uses to monitor events and initiate appropriate responses. While a protein is defined by its backbone of amino acid sequence, its function is often...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BFU2012-35716
CARACTERIZACION DE LA REGULACION DEL PROTAOSMA Y LAS IMPOLIC...
138K€
Cerrado
nbPTMs
A multifaceted platform for exploring nucleotide based post...
2M€
Cerrado
DGIRG
Aberrant ubiquitin mediated proteolysis in oncogenesis
100K€
Cerrado
DECODINGSUMO
Cracking the SUMO Signalling Code
2M€
Cerrado
BFU2012-37116
ESTUDIO FUNCIONAL Y ESTRUCTURAL DE LAS MODIFICACIONES POST-T...
126K€
Cerrado
BFU2009-13245
LAS DEUBIQUITINASAS EN LA REGULACION DE VIAS MOLECULARES IMP...
56K€
Cerrado
Información proyecto Ubl-Code
Duración del proyecto: 66 meses
Fecha Inicio: 2016-04-26
Fecha Fin: 2021-10-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Post-translational modifications (PTMs) of proteins are a major tool that the cell uses to monitor events and initiate appropriate responses. While a protein is defined by its backbone of amino acid sequence, its function is often determined by PTMs, which specify stability, activity, or cellular localization. Among PTMs, ubiquitin and ubiquitin-like (Ubl) modifications were shown to regulate a variety of fundamental cellular processes such as cell division and differentiation. Aberrations in these pathways have been implicated in the pathogenesis of cancer. Over the past decade high-throughput genomic and transcriptional analyses have profoundly broadened our understanding of the processes underlying cancer development and progression. Yet, proteomic analyses and the PTM landscape in cancer, remained relatively unexplored.
Our goal is to decipher molecular mechanisms of Ubl regulation in cancer. We will utilize the PTM profiling technology that I developed and further develop it to allow for subsequent MS analysis. Together with cutting-edge genomic, imaging and proteomic technologies, we will analyze novel aspects of PTM regulation at the level of the enzymatic machinery, the substrates and the downstream cellular network. We will rely on ample in-vitro and in-vivo characterization of Ubl conjugation to:a. Elucidate the regulatory principles of substrate specificity and recognition. b. Understand signalling dynamics in the ubiquitin system. c. Reveal how aberrations in these pathways may lead to diseases such as cancer. Identifying both the Ubl modifying enzymes and the modified substrates will form the basis for deciphering the molecular pathways in which they operate in the cell and the principles of their dynamic regulation. Revealing the PTM regulatory code presents a unique opportunity for the development of novel therapeutics. More broadly, our approaches may provide a new paradigm for addressing other complex biological questions involving PTM regulation.